The importance of serum biglycan levels as a fibrosis marker in patients with chronic hepatitis B
Göster/ Aç
Erişim
info:eu-repo/semantics/openAccessTarih
2017Yazar
Çiftçiler, RafiyeÖzenirler, Seren
Atak Yücel, Ayşegül
Cengiz, Mustafa
Erkan, Gülbanu
Büyükdemirci, Erkan
Sönmez, Cemile
Yılmaz Esendağlı, Güldal
Üst veri
Tüm öğe kaydını gösterKünye
Çiftçiler, R., Özenirler, S., Atak Yücel, A., Cengiz, M., Erkan, G., Büyükdemirci, E. … Yılmaz Esendağlı, G. (2017). The importance of serum biglycan levels as a fibrosis marker in patients with chronic hepatitis B. Journal of Clinical Laboratory Analysis, 31(5). https://dx.doi.org/10.1002/jcla.22109Özet
BackgroundLiver biopsy is recommended in the majority of patients with chronic viral hepatitis for fibrosis evaluation. Because of the potential risks of liver biopsy, many studies related to non-invasive biomarkers of hepatic fibrosis have been performed. We aimed to assess the diagnostic value of serum biglycan as a non-invasive fibrosis marker in chronic hepatitis B patients. MethodsThis study included 120 patients with biopsy-proven hepatitis B patients and 60 healthy controls. Fibrosis stage and necroinflammatory activity were assessed in liver biopsy specimens. Biglycan level was measured using an ELISA assay. ResultsSerum biglycan levels of chronic hepatitis B patients were found to be significantly higher than those of healthy controls (337.3363.0pg/mL vs 189.1 +/- 61.9pg/mL, respectively, P<.001). There was a statistically significant positive correlation between serum biglycan level and fibrosis stage (P=.004; r=.213). Besides, a statistically significant positive correlation was found between serum biglycan level and necroinflammatory activity (P<.001; r=.271). The AUROC of BGN levels was 0.702 for fibrosis stage, differentiating patients from healthy controls with statistical significance (P<.001). The AUROC of BGN levels was 0.632 for necroinflammatory activity score, differentiating patients from healthy controls with statistical significance (P=.004). ConclusionsSerum biglycan might be used as a non-invasive marker of liver fibrosis. Further studies are needed to evaluate the usefulness of this marker.
WoS Q Kategorisi
Q3Scopus Q Kategorisi
Q2Kaynak
Journal of Clinical Laboratory AnalysisCilt
31Sayı
5Koleksiyonlar
- Makale Koleksiyonu [3641]
- PubMed İndeksli Yayınlar Koleksiyonu [4038]
- Scopus İndeksli Yayınlar Koleksiyonu [6268]
- WoS İndeksli Yayınlar Koleksiyonu [6416]